Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery

This article originally appeared here.
Share this content:
Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery
Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery

TUESDAY, Dec. 22, 2015 (HealthDay News) -- For premenopausal women with breast cancer, chemotherapy plus the luteinizing hormone-releasing hormone analogue (LHRHa) triptorelin is associated with higher long-term probability of ovarian function recovery, according to a study published in the Dec. 22/29 issue of the Journal of the American Medical Association.

Matteo Lambertini, M.D., from the Istituto Nazionale per la Ricerca sul Cancro in Genova, Italy, and colleagues examined the long-term results of LHRHa-induced ovarian suppression during breast cancer chemotherapy. Two hundred eighty-one premenopausal women with stage I to III hormone-receptor positive or hormone-receptor negative breast cancer were enrolled and randomized to chemotherapy plus LHRHa (148 patients) or chemotherapy alone (control; 133 patients). Participants were followed for a median of 7.3 years.

The researchers found that the five-year cumulative incidence estimate of menstrual resumption was 72.6 percent in the LHRHa group and 64.0 percent in the control group (hazard ratio [HR], 1.28; 95 percent confidence interval [CI], 0.98 to 1.68; P = 0.07; age-adjusted HR, 1.48; 95 percent CI, 1.12 to 1.95; P = 0.006). The five-year cumulative incidence of pregnancy was 2.1 and 1.6 percent in the LHRHa and control groups, respectively (HR, 2.56; 95 percent CI, 0.68 to 9.60; P = 0.14; age-adjusted HR, 2.40; 95 percent CI, 0.62 to 9.22; P = 0.20).

"Concurrent administration of triptorelin and chemotherapy, compared with chemotherapy alone, was associated with higher long-term probability of ovarian function recovery, without a statistically significant difference in pregnancy rate," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »